Philips teams up with Genomic Health to utilize innovative digital pathology solutions to optimize pre-analytical specimen processing

October 12, 2015

Amsterdam, the NetherlandsRoyal Philips (NYSE: PHG, AEX: PHIA), a leader in the digitization of pathology, today announced a collaboration with Genomic Health, Inc. (NASDAQ: GHDX), a world leading provider of genomic-based diagnostic tests, to leverage Philips’ digital pathology tools in Genomic Health’s continuing scale up of its molecular diagnostic testing processes.   

 

Pathology involves the examination of patient tissue samples and plays a crucial role in the diagnosis and treatment of a wide variety of diseases, including cancer. Philips is a pioneer and leader in the digitization of pathology. Pathologic evaluation of tumor tissue specimens is a critical step in the genomic testing process conducted by Genomic Health’s Clinical Reference Laboratory. These genomic tests support physicians’ ability to deliver personalized treatment for patients diagnosed with complex disease such as cancer.    

 

“Digitization has the potential to open new opportunities for increased efficiency and a reduction in the shortcomings of a traditional analog histopathology workflow,” said Russell Granzow, General Manager of Philips Digital Pathology Solutions. “Philips is driving the evolution towards unified patient data to ensure pathologists are empowered to meet the increasing demand in cancer care for more precise diagnostics.”

 

“By utilizing Philips’ latest digital pathology solution, we are providing our pathologists with a state-of-the-art system that will provide the next level of scalability and efficiency for our overall pre-analytical process, adding new capabilities that will be increasingly important as worldwide demand for Genomic Health’s tests continues to grow,” said Jon Cassel, Senior Vice President of Operations at Genomic Health.

 

Philips’ lntelliSite Pathology Solution* is an automated digital pathology image creation, management and analysis system comprised of an ultra-fast pathology slide scanner, an image management system and case viewer. This solution is complemented by advanced software tools to manage the scanning, storage, presentation, research analysis and sharing of information.

 

* In the European Union, the Philips IntelliSite Pathology Solution is CE Marked under the European Union's 'In Vitro Diagnostics Directive' for in vitro diagnostic use.In Canada, the Philips IntelliSite Pathology Solution is licensed by Health Canada for in vitro diagnostic use. In the United States, the Philips IntelliSite Pathology Solution can be used for in vitro diagnostic use for Manual Read of the Digital HER2 Application and is available for research use only. The Philips IntelliSite Pathology Solution is registered for in vitro diagnostic use in Singapore and Middle East.

For further information, please contact:

Hans Driessen                                                                                   

Philips Digital Pathology Solutions

Tel.: +31 6 10 610 417

E-mail: hans.driessen@philips.com

 

Steve Klink
Philips Group Communications
Tel.: +31 6 1088 8824
E-mail: steve.klink@philips.com 

.

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a diversified health and well-being company, focused on improving people's lives through meaningful innovation in the areas of Healthcare, Consumer Lifestyle and Lighting. Headquartered in the Netherlands, Philips posted 2014 sales of EUR 21.4 billion and employs approximately 106,000 employees with sales and services in more than 100 countries. The company is a leader in cardiac care, acute care and home healthcare, energy efficient lighting solutions and new lighting applications, as well as male shaving and grooming and oral healthcare. News from Philips is located at www.philips.com/newscenter. 

.